BMS-066

• Description:

  BMS-066 is an IKKβ/Tyk2 pseudokinase inhibitor, with IC50s of 9 nM and 72 nM, respectively.

• UNSPSC:

  12352005

• Target:

  IKK; JAK

• Type:

  Reference compound

• Related Pathways:

  Epigenetics; JAK/STAT Signaling; NF-κB; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/BMS-066.html

• Purity:

  99.09

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  CN1C=NC2=C1C(C=C(C3=CC=CC(CNC(COC)=O)=N3)N4)=C4N=C2NC

• Molecular Formula:

  C19H21N7O2

• Molecular Weight:

  379.42

• References & Citations:

  [1]Gillooly KM, et al. Periodic, partial inhibition of IkappaB Kinase beta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritis. J Pharmacol Exp Ther. 2009 Nov;331 (2) :349-60.|[2]Tokarski JS, et al. Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain. J Biol Chem. 2015 Apr 24;290 (17) :11061-74.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  IKK-β; Tyk2

• CAS Number:

  [914946-88-6]